Formulation and Drug Delivery

Merck Joins CAR T-cell Market with $941 Million Intrexon Alliance

March 31, 2015

Merck Serono announces that it will work with Intrexon to develop a cancer therapy using chimeric antigen receptor T-cells.

Rentschler Commissions 2000-L Single-Use Bioreactor

March 30, 2015

Rentschler Biotechnologie launches 2000-L single-use bioreactor and announces additional expansion.

Industry Responds to FDA Labeling Rule

March 30, 2015

Drug makers back alternative to FDA labeling update rule.

FDA Denies Amgen's Certification Petition in Biosimilar Patent Dance

March 30, 2015

Biosimilar applicants will not be required to hand over their biosimilar applications and manufacturing dossiers to innovator companies, determines FDA.

The White House Responds to Superbug Threats

March 27, 2015

The White House confirmed that it would release a plan to tackle the growing problem of antibiotic-resistant superbugs.

Recipharm and Adroit Science Collaborate to Expand Development Services

March 26, 2015

Adroit Science AB will support Recipharm’s pharmaceutical development with solid-state characterization services.

FDA Expands Usage of Regeneron’s Eylea

March 26, 2015

FDA has approved another indication for Eylea, a treatment for diabetic retinopathy in patients with diabetic macular edema.

Emergent Dives Further into the Anthrax Treatment and Vaccine Market

March 25, 2015

Emergent BioSolutions announced FDA approval of Anthrasil, an inhalable treatment that targets Anthrax toxins, as well as a contract with BARDA to develop NuThrax, an anthrax vaccine candidate.

FDA Issues Guidance on Environmental Assessments

March 24, 2015

The agency provides guidance on determining the need for environmental assessments for gene therapies, vectored vaccines, and viral and microbial products.

Novartis' Cosentyx Shows Promise in the Treatment of Psoriasis

March 24, 2015

Clinical trial results suggest that monoclonal antibodies targeting the function of proinflammatory cytokine IL-17A in psoriasis may be significantly superior to other treatments.